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ABSTRACT
Background Longstanding colonic IBD increases 
the risk of developing colorectal cancer. The utility of 
chromoendoscopy with standard- definition white light 
technology has been established. However, the use of 
high- definition virtual chromoendoscopy (HDV) in colitis 
surveillance remains undefined.
Objective To compare the performance of HDV (i- scan 
OE mode 2) with high- definition white light (HDWL) for 
detection of neoplasia in patients with IBD undergoing 
surveillance colonoscopy. Additionally, we assessed the utility 
of protocol- guided quadrantic non- targeted biopsies.
Design A multioperator randomised controlled trial was 
carried out in two centres in the UK. Total of 188 patients 
(101 men, mean age 54) with longstanding ulcerative 
or Crohn’s colitis were randomised, prior to starting the 
surveillance colonoscopy, to using either HDV (n=94) or 
HDWL (n=94) on withdrawal. Targeted and quadrantic 
non- targeted biopsies were taken in both arms per- 
randomisation protocol. The primary outcome was the 
difference in neoplasia detection rate (NDR) between HDV 
and HDWL.
Results There was no significant difference between 
HDWL and HDV for neoplasia detection. The NDR was 
not significantly different for HDWL (24.2%) and HDV 
(14.9%) (p=0.14). All intraepithelial neoplasia (IEN) 
detected contained low- grade dysplasia only. A total of 
6751 non- targeted biopsies detected one IEN only. The 
withdrawal time was similar in both arms of the study; 
median of 24 min (HDWL) versus 25.5 min (HDV).
Conclusion HDV and HDWL did not differ significantly 
in the detection of neoplasia. Almost all neoplasia were 
detected on targeted biopsy or resection. Quadrantic 
non- targeted biopsies have negligible additional gain.
Trial registration number Clinical  Trial. gov ID 
NCT02822352.
INTRODUCTION
Longstanding colonic IBD increases the risk of 
developing colorectal cancer (CRC). The estimated 
prevalence of CRC in patients with longstanding UC 
is 3.7% (95% CI 3.2% to 4.2%).1 The risk of devel-
oping CRC is similarly high in patients with long-
standing Crohn’s colitis (CC).2 The duration of the 
disease is directly proportional to the rates of devel-
oping CRC, with a variable cumulative incidence 
of 1%–2% by 10 years, 4%–8% by 20 years and 
14%–18% by 30 years.1 3 Therefore, national and 
international guidelines recommend patients with 
colonic IBD of 8–10 years duration to be enrolled 
in an endoscopic surveillance programme.4 5
Significance of this study
What is already known on this subject?
 ► Longstanding ulcerative and Crohn’s colitis 
increases the risk of developing colorectal 
cancer (CRC).
 ► Surveillance colonoscopy is recommended by 
national and international guidelines to reduce 
the risk of developing CRC.
 ► Chromoendoscopy using standard- definition 
endoscopes has been shown to improve 
neoplasia detection rate, but the uptake of this 
technique has been low.
 ► The role of high- definition white light (HDWL) 
endoscopy and a novel high- definition virtual 
chromoendoscopy (i- scan OE Mode 2) is not 
known.
What are the new findings?
 ► Our randomised controlled trials did not 
demonstrate the superiority of high- definition 
virtual chromoendoscopy (HDV) over HDWL.
 ► The control group (HDWL) outperformed the 
intervention group (HDV) where targeted 
biopsies with HDWL alone can detect all the 
neoplasia in colitic bowel.
 ► The yield of quadrantic non- targeted biopsies 
in detecting neoplasia is extremely low. A total 
of 6751 non- targeted colonic biopsies detected 
one neoplasia in this study.
How might it impact on clinical practice in the 
foreseeable future?
 ► Targeted biopsies with HDWL endoscopy 
systems may be adequate in detecting 
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These guidelines recommend surveillance colonoscopy using 
chromoendoscopy with targeted biopsy as standard practice. 
Several studies have demonstrated up to threefold increase in 
neoplasia detection (per- patient basis) using chromoendoscopy 
when compared with standard- definition white light endos-
copy.6–9 Despite the higher neoplasia yield by chromoendoscopy, 
the technique has not been widely adopted by endoscopists. This 
is partly due to the perceived additional time taken to carry out 
chromoendoscopy, lack of validated standards and training on 
the chromoendoscopy technique and inability to use the dyes in 
the presence of poor bowel preparation.10
The seminal trials showing the efficacy of chromoendoscopy 
in the detection of neoplasia in colitis were conducted using 
standard- definition white light technology. Carrying out surveil-
lance colonoscopy using high- definition white light (HDWL) 
has been demonstrated to have a higher neoplasia detection rate 
(NDR) when compared with standard- definition white light.11 
The per- patient NDR using HDWL in two recent trials was 
between 0.12 and 0.26, an improvement from the per- patient 
NDR of 0.07 with chromoendoscopy using standard- definition 
white light in the older studies.6 12–14
Advances in technology have led to the development of, dye- 
free virtual chromoendoscopy technologies such as HD i- scan 
(Pentax, Tokyo, Japan) and NBI (Olympus, Tokyo, Japan). These 
technologies enhance the mucosal surface details, thereby theo-
retically improving the detection of neoplasia. However, two 
randomised controlled trials (RCTs) assessing the effectiveness 
of virtual chromoendoscopy over dye spray chromoendoscopy 
have been inconclusive.13 15
The i- scan OE- mode 2 (Pentax, Tokyo, Japan) is a high- 
definition virtual chromoendoscopy (HDV) system that uses 
a combination of bandwidth- limiting filter and digital post- 
processing technology. This technology uses red light emission 
as well as emission at 415 nm and 540 nm to enhance the surface 
of mucosa and the underlying blood vessels while maintaining a 
bright overall appearance, thus making it potentially efficient in 
detecting mucosal lesions in the colon.
The aim of this study was to evaluate the performance of 
HDV when compared with HDWL in patients with longstanding 
colonic IBD undergoing surveillance colonoscopy for neoplasia 
and to evaluate the additional yield of neoplasia detection with 
protocol- guided quadrantic but non- targeted colonic biopsies.
METHODS
Study design
This was a multicentre prospective RCT. The study participants 
were recruited from two centres in the UK (Queen Alexandra 
Hospital, Portsmouth and University Hospital Birmingham, 
Birmingham) between August 2016 and February 2018 (see 
online supplemental file 1)—study protocol).
Patient and public involvement
Patients and a member of public were involved in the trial devel-
opment stage. The group is representative of the local popula-
tion eligible for the trial, and included patients or carers with 
bowel disease. We discussed the trial questions, acceptability 
of trial designs including parallel group versus cross- over and 
methods of recruitment. This group also reviewed patient- facing 
documents such as the informed consent and information sheet.
Patients
All consecutive patients with IBD above the age of 18 years 
with longstanding colitis (UC: 8 years after onset of symptoms 
for patients with subtotal or total colitis and 10 years after 
onset of symptoms for patients with left- sided colitis, CC: 
8 years after diagnosis) referred for a surveillance colonos-
copy and who were able to provide consent were invited to 
participate.
Exclusion criteria were persistent coagulopathy, known colonic 
neoplasia, pregnant women, fulminant colitis and inability to 
consent. Persistent coagulopathy was defined as patients who 
were on warfarin and had an international normalised ratio 
(INR) of >1.5 despite cessation of the drug or had not stopped 
their direct oral anticoagulants as per the British Society of 
Gastroenterology and European Society of Gastrointestinal 
Endoscopy guidelines on endoscopy in patients on anticoagulant 
therapy.16
Procedure
All patients received standard polyethylene glycol- based bowel 
preparation prior to the procedure. The patients were consented 
for the study following consent for the surveillance colonos-
copy. Thereafter, demographic and clinical data were obtained. 
Patients were randomised on a 1:1 ratio to two study arms via 
an online randomisation platform (Sealed Envelope, UK) using 
random permuted blocks of randomly varying sizes prior to 
commencing the surveillance colonoscopy. The disease activity 
and bowel preparation were assessed during the insertion phase 
of the surveillance colonoscopy. Patients with active colitis 
(defined as modified Baron’s score of <3 and Simple Endoscopic 
Score for Crohn’s Disease of <6) and poor bowel preparation 
(defined as >20% of the mucosa obscured by solid stool after 
suction) were withdrawn from the study.
All colonoscopies were carried out using i10 series Pentax 
colonoscopes without zoom and OPTIVISTA EPK- i7010 high- 
definition video processors (Pentax, Germany), which were 
connected to high- definition monitors. The colonoscopies were 
undertaken by six dedicated endoscopists who have been trained 
to perform IBD surveillance colonoscopy by the two senior 
endoscopists in the study (PB and MI). All the endoscopists 
involved had carried out more than a 100 cases using HDV and 
HDWL prior to the commencement of the study. The proce-
dures were performed with the patients under conscious seda-
tion using intravenous midazolam and fentanyl.
Intubation up to the caecum was carried out using HDWL 
in both arms. Once the caecum was reached, withdrawal was 
carried out using i- scan OE mode 2 for patients randomised 
to the HDV arm. For patients in the HDWL arm, withdrawal 
was carried out using HDWL only. A research nurse who was 
present for the whole duration of the procedure documented 
the times for the start of the procedure, caecal intubation and 
the end of the procedure where the colonoscope has been 
completely withdrawn from the patient using an electronic 
clock.
Biopsy protocol
The assessment for lesions was carried out on withdrawal of 
the endoscope from the caecum. The size, location and Paris 
classification of all lesions detected in both arms of the study 
were documented. These lesions were either resected or targeted 
biopsies were taken. No additional imaging technologies or 
techniques were used to assess the lesions prior to resection or 
biopsy. In addition, quadrantic non- targeted biopsies were taken 
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Histopathological assessment
Pathological specimens were analysed by the pathologist of each 
centre for the presence of neoplasia. A second pathologist expert 
in gastrointestinal pathology reviewed all specimens containing 
neoplasia. The following pathological diagnoses were consid-
ered to be neoplastic: adenoma, any grade of dysplasia, serrated 
or adenocarcinoma. Hyperplastic, regenerative, inflammatory 
and pseudopolyps were considered as non- neoplastic.
STATISTICAL ANALYSIS
In previous studies using the older virtual chromoendoscopy 
technologies, the NDR using HDV has been reported to be 
between 12% and 39%.17–19 We have used an expected NDR in 
the HDV arm of 24% and of 9% in the HDWL (control) arm. 
With a significance level (alpha) of 5% and power of 80%, the 
number needed was 93 in each group, leading to a total of 186. 
However, we anticipated a 10% attrition rate after the colonos-
copy has been started (eg, poor bowel preparation, endoscopi-
cally confirmed moderate to severe colitis). To adjust for this, we 
decided to recruit 204 patients.
The rate of neoplastic lesions detected with either endoscopic 
technique was analysed using a statistics software programme 
(SPSS V.24.0, IBM Armonk, New York, USA). The analyses 
were conducted on a ‘per- patient’ and ‘per- lesion’ basis. The 
‘per- patient’ analysis was done by calculating the percentage 
of patients in whom true neoplastic lesions were detected from 
biopsies of endoscopically suspicious lesions. On the other hand, 
in ‘per- lesion’ analysis, the percentage of neoplastic lesion among 
all endoscopically suspicious lesions was calculated. Fisher’s 
exact test and χ2 test, where deemed appropriate, were applied 
for dichotomous variables. A Mann- Whitney U test or Student’s 
t- test was used for continuous variables. P values <0.05 were 
considered significant for the analysis.
RESULTS
We enrolled 204 patients in the study between August 2016 and 
February 2018. Sixteen patients were excluded after randomis-
ation due to poor bowel preparation, severe colitis, impassable 
inflammatory stricture, unresolvable looping, impassable diver-
ticular stricture and withdrawal of consent. (figure 1). A total 
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of 184 patients (92 in the HDWL and 92 in the HDV arms) 
were included in the final analysis. The baseline characteristics 
of patients in both arms did not differ (table 1). There were no 
adverse events in this study.
Primary endpoint
A total of 27 neoplastic lesions were detected in 22 patients in 
the HDWL arm (n=92) and 25 neoplastic lesions were detected 
in 14 patients in the HDV arm (n=92). The NDR was slightly 
higher in the HDWL arm (23.4%) when compared with the HDV 
arm (14.9%) but the difference was not statistically significant 
(p=0.14). (table 2) An example of a neoplastic lesion detected 
using HDWL and HDV is shown in figure 2. The number of 
patients in each arm with neoplastic lesions and the characteris-
tics of the lesions detected are detailed in table 3.
Secondary endpoints
The mean neoplasia per- patient in the HDWL arm was 0.29 and 
in the HDV arm was 0.26. This difference was not statistically 
significant (p=0.75). The number of non- targeted quadrantic 
biopsies taken in the HDWL and HDV arm was 3373 and 3378, 
respectively. The mean number of biopsies taken per- patient 
was 35.9 in each arm. Only one neoplasia (low- grade dysplasia 
within a segment of active colitis in the HDWL arm) was detected 
on quadrantic non- targeted biopsies in this study, otherwise all 
neoplasias were detected on targeted biopsy.
The number of sessile serrated lesions (SSL) detected was 13 
in the HDWL arm and 4 in the HDV arm of the study. These 
lesions were all located in the right colon; nine in the transverse 
colon, seven in the ascending colon and one in the caecum. On 
a per- patient analysis, SSLs were seen more frequently in the 
HDWL arm (8/98 vs 4/98 patients).
There was no difference in the total withdrawal time in either 
arm of the study; 24.0 (IQR 20.0–30.0) min in the HDWL arm 
and 25.5 (IQR 21.0–31.0) min in the HDV arm (p=0.216). The 
difference in the mean total withdrawal time in patients where 
targeted lesions were biopsied or resected in either study arm 
was not statistically significant; 29.0 (IQR 22.8–31.3) min in 
the HDWL arm and 31.6 (IQR 25.0–37.0) min in the HDV arm 
(p=0.11).
DISCUSSION
In this multioperator multicentre randomised control trial, 
we did not demonstrate a significant difference between HDV 
and HDWL in the detection of neoplasia in patients with long-
standing IBD. Furthermore, we did not find any difference in 
the total number of neoplasia and the ratio of non- neoplastic 
to neoplastic lesions detected in either arm of the study. To our 
knowledge, this is the first multicentre randomised control trial 
assessing the utility of a novel i- scan OE mode 2 in the detection 
of neoplasia during colitis surveillance.
The NDR in this study was similar to other studies investi-
gating the utility of NBI.15 20 However, unlike these studies, a 
larger proportion of the neoplastic lesions detected in our study 
were flat (Paris IIa/IIb): 81% versus 32%–58% in previously 
reported literature. This is possibly due to the overall bright 
appearance of the mucosa in both arms of this study that is 
not usually seen easily with narrow band technologies due to 
the darkening effects of these technologies. In addition, more 
intraepithelial neoplasias were detected with HDV and HDWL 
detected more SSLs. SSLs tend to have mucous caps, thereby 
obscuring the surface patterns altogether. With HDV, faecal 
residue and mucous have the same colour. The small numbers 
of these lesions make it difficult to make meaningful statistical 
conclusions.
This study did not compare chromoendoscopy versus HDWL. 
However, previous guidelines including Surveillance for Colorectal 




OR (95% CI) Fisher’s exact p value
Age in years, median (IQR, p25–p75) 53.7 (20 to 79) 54.3 (21 to 80) 0.786
Sex (M:F) 46:48 55:39 0.242
Type of colitis, n (%)
  UC 60 (64) 69 (73) 0.204
  Concurrent primary sclerosing cholangitis 1 (1) 1 (1)
  Crohn’s colitis 33 (35) 24 (26) 0.204
Distribution of colitis, n (%)
  Left sided 15 (16) 23 (24) 0.203
  Subtotal/total 79 (84) 71 (76) 0.203
  Duration of illness in years, median (IQR, p25–p75) 17.0 (13 to 27.5) 18.0 (13.3 to 25.8) 0.635
  Left sided 19.0 (15.5 to 22.5) 23.0 (17.5 to 26.0)
  Subtotal/total 17.0 (12.5 to 28.0) 16.0 (12.5 to 25.5)
Therapy, n (%)
  Steroids 2 (2) 1 (1) 1
  ASA 76 (81) 80 (85) 0.561
  Immunosuppressant 29 (31) 27 (29) 0.873
  Biologics 9 (10) 6 (6) 0.592
ASA, aminosalicylic acid; HDV, high- definition virtual chromoendoscopy; HDWLE, high- definition white light.





Total number of targeted lesions detected 71 78
Number of neoplastic lesions detected 27 25
Number of patients with at least one neoplastic lesion 22 14
Neoplasia detection rate 23.4% 14.9%
Neoplasia detection rate: Fisher’s exact p value=0.14.
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Endoscopic Neoplasia Detection and Management in Inflamma-
tory Bowel Disease Patients: International Consensus Recommen-
dations (SCENIC) recommend the use of chromoendoscopy based 
on the evidence from a single observational study that found that 
the NDR with HDWL alone was 9% and when used with chro-
moendoscopy, the NDR was 21%.21 22 The findings in our RCT 
show that HDWL on its own has an NDR of 23.4%. This detec-
tion rate is comparable to other established techniques in colitis 
surveillance colonoscopy including high- definition chromoendos-
copy.14 15 20 23 24 This will certainly add to the discussion in future 
guidelines that HDWL on its own may be sufficient to carry out an 
effective colitis surveillance colonoscopy.
International IBD surveillance guidelines recommend chro-
moendoscopy in IBD surveillance. However, adherence to 
these guidelines has been poor.25 26 The basic minimum for IBD 
surveillance colonoscopy has been and still is quadrantic non- 
targeted colonic biopsies. In a recent survey among international 
IBD physicians and endoscopists, up to 43% of respondents 
stated that they perform non- targeted colonic biopsies in >75% 
of cases when performing surveillance with chromoendos-
copy.10 In our study, a total of 6751 non- targeted biopsies were 
taken and only 1 was reported to contain neoplasia (low- grade 
dysplasia with active background disease). Our findings add to 
the body of evidence on the futility of non- targeted biopsies in 
detecting neoplasia.27 28 In the era of high- definition endoscopy 
systems, it is time to abandon costly and ineffective quadrantic 
non- targeted biopsies during IBD surveillance colonoscopy.
Increased withdrawal times have been shown to increase 
adenoma detection rates in colonoscopies done on patients with 
non- IBD.29 In our study, the withdrawal time was between a 
median of 24.0 and 25.5 min in each study arm. This is likely 
to be due to the 6751 non- targeted biopsies that were taken as 
part of the study protocol. The design of our study allows us 
to conclude that quadrantic non- targeted biopsies do not make 
any significant additional contribution to NDR over and above 
the targeted biopsies. However, we cannot completely exclude 
the impact of long withdrawal time on NDR rate in our study. 
If quadrantic non- targeted biopsies were to be abandoned, the 
withdrawal times could be shortened. A recent systematic review 
and experts’ opinion recommends that the withdrawal time of 
17 min should be considered as one of the key performance 
indexes of colitis surveillance.30 Therefore, it may be benefi-
cial for patients’ undergoing colitis surveillance to be allocated 
extra time to allow for careful assessment of the colonic mucosa 
during withdrawal.
One of the strengths of this study is the randomised multicentre 
design involving several endoscopists. While previous studies 
were often carried out in tertiary referral centres, patients in this 
study were recruited through a general IBD surveillance popula-
tion. An additional strength of our study is that quadrantic non- 
targeted biopsies were taken in both arms, thereby reducing the 
risk of missing ‘invisible’ neoplastic lesions.
There were several limitations to this study. As it is a parallel 
study, it was not possible to calculate the miss rate of neoplasia. 
However, a cross- over trial will require a long washout period 
and a second colonoscopy. A back- to- back trial would introduce 
a ‘double- look’ bias. Both of these trial designs were found to 
be unacceptable to our patient and public involvement group. 
The second limitation is that although the participating endos-
copists were experienced in the use of advanced imaging tech-
nologies including i- scan and in IBD surveillance, there was no 
Figure 2 Example of a neoplastic lesion detected with HDWL and HDV. In picture (A), the lesion is seen using HDWL and in picture (B), the same 
lesion is seen using HDV. The histology of this lesion was tubular adenoma with low grade dysplasia. HDV, high- definition virtual chromoendoscopy; 
HDWLE, high- definition white light.
Table 3 The number of patients with lesions and the characteristics 
of lesions detected
HDWL (n=94) HDV (n=94)
Fisher’s exact
p value
Total number of lesions 
identified
71 78 0.21
Total number of 
neoplastic lesions
27 25 0.49
Paris classification of lesions
  IIa 18 19 0.55
  IIb 2 3 0.32
  IIa–c 1 0 0.33
  Is 6 3 0.33
Size of neoplastic lesions 
in mm, median (range)
4.30 (2–15) 3.16 (1–20) 0.24
Number of lesions according to histology




  Intraepithelial neoplasia (colitis areas)
  Low grade 13 22
   High grade 0 0
   Adenocarcinoma 1 0
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validated classification for characterisation of neoplastic lesions 
in IBD colon with i- scan at the time the study was conducted. 
Despite this, however, the NDR was comparable to other similar 
studies. The NDR in the HDV group was lower compared with 
other studies. However, non- targeted biopsies in the HDV group 
did not pick up any additional neoplasia. Our trial design that 
includes targeted and non- targeted quadrantic biopsies provide 
the confidence to state that the lower HDV detection rate was 
not due to high miss rate of HDV.
Patients recruited in this study were not stratified based on their 
type of IBD or by gender. Therefore, the imbalance of the number 
of patients with UC and the male preponderance of patients in the 
HDV arm of the study arose by chance. The study was focused 
on the overall detection by the different imaging platforms, and 
therefore, we did not focus on gender or specific lesions identified. 
There is no convincing evidence in the literature that such gender 
differences occur or that lesions are different in UC versus CC. 
An interesting finding was that the neoplasia per- patient detected 
was higher with HDV (25 lesions in 14 patients) than it was with 
HDWL (27 lesions in 22 patients). This is a useful marker of effi-
cacy but it has not been adopted by other similar studies, thereby 
making it difficult to compare and contrast the study findings. 
Additionally, our study was not powered based on the neoplasia 
per- patient rate. A meaningful deduction, therefore, cannot be 
made based on this finding.
In conclusion, in this multicentre RCT, we could not demon-
strate a significant difference in NDR between HDV (i- scan 
OE mode 2) and HDWL. However, IBD surveillance using 
a high- definition endoscopy system achieved high NDR. This 
technology on its own may be sufficient to detect neoplasia in 
patients with longstanding IBD.
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